Rising to the Challenge: The Evolving Landscape of Maintenance Therapy in Ovarian Cancer

Target Audience
This activity is intended for medical oncologists and gynecologic oncologists, and other HCPs who provide care for patients with ovarian cancer.

Program Overview
The landscape of maintenance treatment options for ovarian cancer has been rapidly expanding and continues to evolve as new data emerge. Maintenance therapy with poly(ADP-ribose) polymerase (PARP) inhibitors and bevacizumab has demonstrated improvements in progression-free survival. A recent trial showed that maintenance therapy involving a PARP inhibitor improved overall survival in patients with platinum-sensitive recurrent ovarian cancer associated with BRCA1/2 mutations. In this enduring activity, an expert will examine relevant advances in genetic biomarker testing to individualize therapy, assess recent efficacy and safety data related to PARP inhibitors and bevacizumab maintenance therapy, and review strategies to effectively prevent and manage adverse effects.

Learning Objectives
Upon completion of this activity, participants should be better able to:

SUMMARIZE the rationale for maintenance therapy in ovarian cancer
EVALUATE the efficacy and safety results of available maintenance therapies in ovarian cancer to tailor treatment recommendations
IMPLEMENT individualized strategies to effectively manage and prevent adverse events for ovarian cancer maintenance therapy
UTILIZE genetic biomarker testing for individualized treatment and prevention recommendations for women with or at risk for ovarian cancer